Multiple B-cell epitope vaccine induces a Staphylococcus enterotoxin B-specific IgG1 protective response against MRSA...

Area of Science:

• Vaccinology
• Microbiology
• Immunology

Background:

• No approved human vaccine currently exists for methicillin-resistant Staphylococcus aureus (MRSA).
• Staphylococcus enterotoxin B (SEB) is a significant MRSA exotoxin contributing to infection severity.
• Developing effective vaccines against MRSA remains a critical unmet medical need.

Purpose of the Study:

• To evaluate the efficacy and immunologic mechanisms of a novel SEB multiple B-cell epitope vaccine against MRSA infection.
• To identify and characterize immunodominant B-cell epitopes of SEB for vaccine development.
• To assess the protective potential of a recombinant vaccine (Polypeptides) composed of multiple SEB epitopes.

Main Methods:

• Synthetic overlapping peptide ELISA was employed to identify novel SEB B-cell epitopes.
• Six key SEB immunodominant epitopes were selected for vaccine construction.
• A recombinant vaccine, Polypeptides, was synthesized by combining these epitopes.
• The vaccine's efficacy was tested in MRSA-infected mouse models, assessing bacterial clearance and survival.

Main Results:

• Three novel SEB B-cell epitopes were identified, alongside previously known ones.
• A combination of six SEB epitopes induced robust IgG1/IgG2b-specific protective responses.
• The Polypeptides vaccine elicited a strong SEB-specific IgG1 response and a Th2-directing isotype response.
• Polypeptides-induced antisera enhanced MRSA killing through opsonophagocytosis.
• The vaccine demonstrated superior bacterial clearance in mice compared to whole SEB antigen and protected against diverse clinical MRSA isolates.

Conclusions:

• The developed SEB multiple B-cell epitope vaccine (Polypeptides) is effective in clearing MRSA in a preclinical model.
• The vaccine induces robust humoral immunity and enhances bacterial killing mechanisms.
• These findings support the further development of this SEB epitope-based vaccine for human MRSA infections.